Compare Gilead Sciences, Inc. (GILD) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Gilead Sciences, Inc. trades at $132.93 (market cap $163.51B), while YieldMax NVDA Option Income Strategy ETF trades at $12.56. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| GILD | NVDY | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $17.96 |
52-Week Low | $108.22 | $12.03 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.60, down 1.56% with a mixed technical outlook showing bullish overall signals but bearish moving averages. The ETF generates weekly income through NVIDIA option strategies, with recent distributions ranging from $0.10-$0.21 per share. Technical analysis indicates support at $12-$13 levels while fundamental metrics remain unavailable for this income-focused strategy.
The ETF offers high-income potential through systematic option selling on NVIDIA shares but sacrifices significant upside participation. Recent articles highlight the trade-off between income generation and missed NVIDIA gains, with the 1.09% management fee impacting returns. Key risks include NVIDIA volatility exposure and the strategy's capped upside during strong market moves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
